Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasms 2Neoplasm Metastasis 2Urogenital Neoplasms 1Prostatic Diseases 1Neoplasms, Glandular and Epithelial 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-resistant Prostate Cancer 1Genital Neoplasms, Male 1Carcinoma 1Adenocarcinoma 1

Interventions

sipuleucel-T 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castrate-resistant Prostate Cancer × sipuleucel-T × Clear all
NCT01818986 2022-05-06

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

University of Texas Southwestern Medical Center

Phase 2 Completed
20 enrolled 13 charts
Genitourinary

Metastatic Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡